MAPT and Alzheimer disease: However, our preclinical models do not recapitulate all aspects of end-stage (Braak VI) AD, notably the development of tau neurofibrillary pathology, a neuroinflammatory reaction to neuropathology and changes to the blood brain barrier, all of which may contribute to the dramatic increase in cathepsin B activity we observed in individuals who have EOAD.